Therefore, elevated FABP4 may serve as a potential biomarker for hepatic lipid metabolic dysfunction and inflammatory status and could be a promising therapeutic target for MASLD and its complications [38]. This evidence concerns the gene FABP4 and metabolic dysfunction-associated steatotic liver disease.